A “Fine Line:” CMS’ Jacques On Coverage-With-Evidence Requirements
This article was originally published in The Gray Sheet
Executive Summary
Medicare coverage director Louis Jacques describes the necessary balancing act to gauge the appropriate level of data requirements for a coverage-with-evidence-development policy.
You may also be interested in...
New Coverage-With-Evidence-Development Guidance In The Works Following MedCAC Meeting
The Medicare Evidence Development & Coverage Advisory Committee was charged May 16 with helping CMS better define the evidence threshold under which the agency should or should not pursue a coverage- with-evidence-development policy.
Device Makers Want Say In Medicare 'Coverage-With-Evidence-Development' Policy
Manufacturers seek more input on trial designs and objectives when CMS takes the "coverage-with-evidence-development" route to national Medicare coverage.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.